icon

$0 Co-Pay Program

Rubraca is available at $0 co-pay to 100% of commercially insured patients, regardless of income.

icon

Text-based support

The Clovis4YOU text message support program is a personalized patient program with medication reminders, daily tips, emotional support, and more that can help you throughout treatment.

icon

FAQs

The most commonly asked questions about taking Rubraca for recurrent ovarian cancer.

Resources for women taking Rubraca

Here are tools to download, and a list of ovarian cancer organizations you can access to support yourself, family members, and care partners

Brochure imageBrochure image

Take the Patient Brochure with you. It has even more information on how Rubraca might be right for you.

Download the Patient Brochure (English)icon Download the Patient Brochure (Spanish)icon

Organizations supporting women, family members, and care partners impacted by ovarian cancer

American Cancer Society

Funds and conducts research, shares information from experts, supports patients.

visit
CancerCare

Provides telephone, online, and face-to-face counseling, support groups, education, publications, and financial assistance.

visit
Clearity Foundation

Provides patient support services including lab test coordination, tumor blueprint interpretation, and clinical trial identification free of charge.

visit
FORCE: Facing Our Risk of Cancer Empowered

Provides education, advocacy, and research specific to hereditary breast and ovarian cancer.

visit
Foundation for Women‘s Cancer (FWC)

Supports cancer research, education, and public awareness of gynecologic cancers, including risk information, prevention, early detection, and optimal treatment. A partner of the Society of Gynecologic Oncology (SGO).

visit
National Cancer Institute

Leads, conducts, and supports cancer research to advance scientific knowledge and help all people live longer, healthier lives. The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training.

visit
National Ovarian Cancer Coalition (NOCC)

Educates communities with national and local programs, increases awareness, provides information and support to patients and caregivers.

visit
OncoLink

Provides web-based patient and professional oncology education designed to be a one-stop shop.

visit
Ovarcome

Raises global awareness on ovarian cancer, funds research in search of a cure, and provides financial assistance to underserved ovarian cancer patients in need.

visit
Ovarian Cancer Research Alliance (OCRA)

Advances research to prevent, treat, and defeat ovarian cancer; supports women and their families before, during, and beyond diagnosis; and works with all levels of government to ensure ovarian cancer is a priority.

visit
Sandy Rollman Ovarian Cancer Foundation

Raises awareness about ovarian cancer, educates the general public and physicians about the disease, and raises funds to advance research toward a cure. The organization also offers support to those fighting the disease.

visit
SHARE

Provides education and community support specific to breast or ovarian cancer with a special focus on medically underserved communities. All services are provided in English and Spanish and include support groups, expert-led educational programs, national helplines, online communities, caregiver support, and survivor-patient navigation.

visit

You are now leaving the Rubraca.com website.

The link you have selected will take you to a third-party site. Clovis Oncology is not responsible for the content on third-party sites. You are encouraged to read the Terms and Conditions and Privacy Policy of the third-party site.

Click CANCEL to return to Rubraca.com. To proceed, click CONTINUE.

Assistance program
Get personalized assistance with
a text-based support program
Enroll in Clovis4YOU today

Glossary

Adverse reaction: any unexpected or dangerous reaction as a result of taking medication.
Antiemetics/antinausea medication: drugs taken to prevent or treat nausea and vomiting.
BRCA mutation: Breast Cancer susceptibility genes, or BRCA, mutations increase the likelihood of developing ovarian cancer.
Clinical trial: research that is designed to test new medical approaches, such as new medicines, and find out if they work and are safe for people.
Complete response, or CR: when the total size of the tumors shrinks to the point where they can no longer be detected on a scan.
DNA (deoxyribonucleic acid): molecules that tell your cells how to survive and grow.
Disease progression: cancer that continues to grow or spread.
Genes: a set of coded instructions in cells for making new proteins and controlling how cells behave.
Germline BRCA mutation: also called an inherited mutation, meaning the gene mutation is passed down from parent to child. Germline mutations are present in every cell in the body, not just in the tumor cells.
HRD mutation: Certain genetic mutations can weaken the way your cells repair DNA damage, causing their repair mechanism to be deficient. These cells have a homologous recombination deficiency, or HRD.
Median: the middle number in a range of numbers, half of which are above and half of which are below. In the following list of numbers—5, 6, 10, 12, 25—the median is 10.
Objective response rate, or ORR: the proportion of patients with a reduction in tumor size by a predefined amount and for a minimum duration. The FDA has defined ORR as the sum of partial and complete responses.
Partial response, or PR: tests show a decrease in the amount of cancer or tumor size in response to treatment, but the cancer is not completely gone.
PARP: poly (ADP-ribose) polymerase, a protein that helps cells repair their DNA when it has been damaged (ie, by chemotherapy or your body’s own immune system).
Placebo: a substance that does not contain any active medication.
Platinum-based chemotherapy: chemotherapeutic agents containing the metal platinum, which is an important component of some anticancer drugs.
Poly (ADP-ribose) polymerase (PARP) inhibitor: a medicine that blocks PARP in cancer cells to prevent DNA repair and cause them to die. PARP inhibitors may also impact other cells and tissues.
Progression-free survival, or PFS: the length of time during and after a treatment that a person continues to live without the disease getting worse.
Response: therapeutic effect of treatment.
Rubraca maintenance: taking Rubraca to stop cancer from growing or spreading.
Rubraca treatment: taking Rubraca to shrink (treat) your cancer after 2 or more rounds of chemotherapy and testing positive for a certain BRCA mutation.
Side effect: a problem that may occur when treatment affects healthy tissues or organs.
Somatic BRCA mutation: also called an acquired mutation, meaning the gene mutation is not passed down from parent to child, but occurs randomly and can develop at any time. Somatic mutations are only present in the tumor cells.
Watchful waiting: when an oncologist does not provide medicine but closely watches the disease to see if symptoms appear or change. Watchful waiting is often adopted when the risks of treatment outweigh the benefits. Tests and exams can also be used at this time to monitor the disease.

We at Clovis Oncology admire the strength and courage of women living with recurrent ovarian cancer, and extend our sincere gratitude to participants of the Rubraca clinical trials.

What is Rubraca used for?

Rubraca is a prescription medicine used for:

  • The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children.

What warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

You should not use Rubraca if you:

  • Are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca
    • Talk to your healthcare provider about birth control methods that may be right for you
    • Tell your healthcare provider right away if you become pregnant
  • Are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for women in the Rubraca clinical studies were nausea, tiredness/weakness, stomach pain, rash, altered taste, decrease in hemoglobin, changes in liver or kidney function blood tests, constipation, vomiting, diarrhea, decrease in platelets, upper respiratory tract infection, mouth sores, decreased appetite, shortness of breath, and decrease in white blood cell count.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information for Important Safety Information.